Like so many things in critical care, angioedema is difficult to research since it is uncommon, heterogeneous, and emergent. As such, we have relatively little high-quality evidence regarding this disease (and the high-quality evidence that we do have is largely restricted to pharma-sponsored trials of new and insanely expensive pharmaceuticals). This chapter attempts to create rational treatment strategies, while acknowledging that definitive data doesn't exist.
The IBCC chapter is located here.
- The podcast & comments are below.
Follow us on iTunes
The Podcast Episode
Want to Download the Episode?
Right Click Here and Choose Save-As
Latest posts by Josh Farkas (see all)
- PulmCrit-The Rothman Index:Artificial intelligence or merely a symptom of a broken healthcare system? - January 25, 2020
- IBCC chapter & cast – Toxic Alcohols - January 23, 2020
- PulmCrit – An alternative view of the PEPTIC trial - January 22, 2020